Helicobacter pylori infection
Conditions
Interventions
Experimental group A:esomeprazole 20mg 2/day, bismuth 220mg 2/day, amoxicillin 1g 2/day, clarithromycin 500mg 2/day. The course of treatment was 10 days
Experimental group B:VPZ 20 mg 2/day and Amoxicillin 1g 2/day for 10 days
Experimental group C:VPZ 20 mg 2/day and Amoxicillin 750mg 4/day for 10 days
Sponsors
Jiangsu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years; 2. Chronic gastritis with or without healed duodenal or stomach ulcer; 3. H. pylori (+) determined by C13 or C14; 4. Treatment-naive patients for eradication of H. pylori infection.
Exclusion criteria
Exclusion criteria: 1. Allergy to medications used in this clinical trial; 2. Use of PPI, histamine H2-receptor antagonists, antibiotics, bismuth, or probiotics 4 weeks before initiating study treatment; 3. Use of adrenocorticosteroids, nonsteroidal anti-inflammatory drugs, and anticoagulants; 4. Alcohol abuse; 5. Presence of diseases or clinical conditions, such as liver disease, cardiac vascular disease,lung disease, kidney disease, metabolic disease, mental illness, or malignant tumors, that might interfere with the evaluation of study treatment; 6. Female patients planning pregnancy, as well as pregnant and breastfeeding patients; 7. Previous esophageal or stomach surgical procedures; 8. Participation in other clinical studies within 3 months before enrollment in this clinical study; 9. Incomplete follow-up or noncompliance with the study treatment; 10. Patients who cannot sign informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient compliance;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactZhang guoxin
Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed